Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Apr 4;12:33. doi: 10.1186/s12918-018-0554-1

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s). 2018

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

PMC Copyright notice

Fig. 1 — Establishing mitogen activated protein kinase inhibitor-resistant melanoma models. a A mitogen activated protein kinase BRAF inhibitor-resistant (BRAFi-R) model was established using SK-MEL-28 and A375 malignant melanoma cell lines. Schedule of administered concentrations of mitogen activated kinase inhibitor, vemurafenib. b Phase contrast images of control SK-MEL-28 parental melanoma cell lines and (c) BRAF inhibitor-resistant SK-MEL-28-BRAFi-R melanoma cell line 1. Black bar indicates 1.0 μm. White arrows in image of resistant cell lines point to cellular structures typical for differentiated melanocytes. d and e Cell viability assay on melanoma cell lines at 10 μM vemurafenib. Absorption in XTT assay is measured at 570 nm. White squares indicate control melanoma cell lines, red triangles and diamonds show melanoma BRAFi-R model. f IC50 concentrations of vemurafenib of control and drug-resistant cancer cell lines